Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 11/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.43 |
| ▸ | PDE8B | O95263 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5731043 | 0.94 | ADORA1 (0.47) | TLR7ADORA1PDE8BADORA2AADORA2B | |
| SCHEMBL5731972 | 0.88 | TLR7 (0.46) | TLR7ADORA1PDE8BADORA2AADORA2B | |
| SCHEMBL5730847 | 0.84 | TLR7 (0.43) | TLR7ADORA1PDE8BADORA2AADORA2B | |
| SCHEMBL5731872 | 0.84 | TLR7 (0.43) | TLR7ADORA1ADORA2AADORA2BMAPK1 | |
| SCHEMBL5731379 | 0.84 | TLR7 (0.45) | TLR7ADORA1ADORA2AADORA2BMAPK1 | |
| SCHEMBL2060517 | 0.84 | TLR7 (0.45) | TLR7ADORA1ADORA2AADORA2BMAPK1 | |
| SCHEMBL10174942 | 0.83 | TLR7 (0.49) | TLR7ADORA1ADORA2A | |
| SCHEMBL5731164 | 0.81 | TLR7 (0.55) | TLR7ADORA1ADORA2AADORA2B | |
| SCHEMBL2060226 | 0.81 | TLR7 (0.43) | TLR7ADORA1PDE8BADORA2AADORA2B | |
| SCHEMBL5731575 | 0.81 | TLR7 (0.40) | TLR7ADORA1ADORA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1043021-B1 | PURINE DERIVATIVES FOR THE TREATMENT OF ALLERGIC DISEASES AND SYSTEMIC LUPUS ERYTHEMATOSUS | DAINIPPON SUMITOMO PHARMA CO (JP) | 2006-05-03 | — | — | EP | disclosed |
| EP-0882727-B9 | NOVEL PURINE DERIVATIVES | SUMITOMO PHARMA (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-0882727-B1 | NOVEL PURINE DERIVATIVES | SUMITOMO PHARMA (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-6376501-B1 | INHIBITING OR REGULATING IMMUNE RESPONSE USING PURINE-DERIVED COMPOUND; NON-STEROIDAL COMPOUND | JAPAN ENERGY CORPORATION (JP) | 2002-04-23 | — | — | US | disclosed |
| EP-1043021-A1 | TYPE 2 HELPER T CELL-SELECTIVE IMMUNE RESPONSE SUPPRESSORS | Japan Energy Corporation (JP) | 2000-10-11 | — | — | EP | disclosed |
| US-6028076-A | FOR INDUCING .ALPHA.-INTERFERON IN A PATIENT HAVING HEPATITIS B OR C, BY ADMINISTERING PURINE DERIVATIVE | JAPAN ENERGY CORPORATION (JP) | 2000-02-22 | — | — | US | disclosed |
| EP-0882727-A1 | NOVEL PURINE DERIVATIVES | JAPAN ENERGY CORPORATION (JP) | 1998-12-09 | — | — | EP | disclosed |